966 results on '"Alavi, Afsaneh"'
Search Results
2. Autoimmune, Autoinflammatory Disease and Cutaneous Malignancy Associations with Hidradenitis Suppurativa: A Cross-Sectional Study
3. Monoclonal gammopathy in the setting of Pyoderma gangrenosum
4. Wound bed preparation 2024: Delphi consensus on foot ulcer management in resource-limited settings
5. IRAK4 degrader in hidradenitis suppurativa and atopic dermatitis: a phase 1 trial
6. An approach to diagnosis and management of patients with pyoderma gangrenosum from an international perspective: results from an expert forum
7. Wound bed preparation
8. Expert consensus on priority research gaps in dietary and lifestyle factors in hidradenitis suppurativa: a Delphi consensus study
9. Eligibility Criteria for Active Ulcerative Pyoderma Gangrenosum in Clinical Trials: A Delphi Consensus on Behalf of the UPGRADE (Understanding Pyoderma Gangrenosum: Review and Assessment of Disease Effects) Group
10. Lower Extremity Angiosarcoma: A Life-Threatening Complication of Lymphedema
11. Comorbidity screening in hidradenitis suppurativa: Evidence-based recommendations from the US and Canadian Hidradenitis Suppurativa Foundations
12. Neutrophilic Panniculitides
13. Palisaded Neutrophilic Granulomatous Dermatitis, Bowel-Associated Dermatosis–Arthritis Syndrome, and Rheumatoid Neutrophilic Dermatitis
14. Efficacy and safety of the oral Janus kinase 1 inhibitor povorcitinib (INCB054707) in patients with hidradenitis suppurativa in a phase 2, randomized, double-blind, dose-ranging, placebo-controlled study
15. The “Understanding Pyoderma Gangrenosum, Review and Assessment of Disease Effects (UPGRADE)” Project: a protocol for the development of the core outcome domain set for trials in pyoderma gangrenosum
16. IRAK4 Is Overexpressed in Hidradenitis Suppurativa Skin and Correlates with Inflammatory Biomarkers
17. Real-World Findings on the Characteristics and Treatment Exposures of Patients with Hidradenitis Suppurativa from US Claims Data
18. Suggestions for a New Clinical Classification Approach to Panniculitis Based on a Mayo Clinic Experience of 207 Cases
19. Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials
20. Candida Infection Associated with Anti-IL-17 Medication: A Systematic Analysis and Review of the Literature
21. Cutaneous Adverse Reactions Following Influenza Vaccination in Adults
22. Discrepancies in hidradenitis suppurativa lesion characterization by providers and patients
23. Inflammatory and vaso-occlusive ulcers: Part II - Management
24. Differentiating generalized pustular psoriasis from acute generalized exanthematous pustulosis
25. Inflammatory and vaso-occlusive ulcers: Part I - clinical presentation and diagnosis
26. The role of mast cells and related molecules in itch of hidradenitis suppurativa
27. Medical Management of Hidradenitis Suppurativa with Non-Biologic Therapy: What’s New?
28. North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations Part II: Topical, intralesional, and systemic medical management
29. North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations Part I: Diagnosis, evaluation, and the use of complementary and procedural management
30. Are Bacteria Infectious Pathogens in Hidradenitis Suppurativa? Debate at the Symposium for Hidradenitis Suppurativa Advances Meeting, November 2017
31. Proceeding report of the Second Symposium on Hidradenitis Suppurativa Advances (SHSA) 2017
32. Vascular Studies for Nonvascular Surgeons
33. Wound Healing in Pyoderma Gangrenosum
34. Wound Healing in Hidradenitis Suppurativa
35. The Basic Principles in Local Wound Care
36. Clinical Characteristics and Inciting Agents for Pseudoporphyria: The Mayo Clinic Experience, 1996-2020.
37. Inpatient Management of Hidradenitis Suppurativa: A Delphi Consensus Study.
38. Value of dermatology hospital conference as a continuing medical education‐accredited activity: A retrospective review.
39. Contributors
40. Clinical Manifestation and Phenotypes of Hidradenitis Suppurativa
41. The Global Hidradenitis Suppurativa Atlas (GHiSA) Methodology: Combining Global Proportions in a Pooled Analysis
42. Wound Bed Preparation 2024: Delphi Consensus on Foot Ulcer Management in Resource-Limited Settings
43. Allergic Contact Dermatitis in Patients With Hidradenitis Suppurativa: A Retrospective Analysis
44. Treatment of pyoderma gangrenosum in pregnancy with certolizumab pegol
45. Value of dermatology hospital conference as a continuing medical education‐accredited activity: A retrospective review
46. Eligibility Criteria for Active Ulcerative Pyoderma Gangrenosum in Clinical Trials: A Delphi Consensus on Behalf of the UPGRADE (Understanding Pyoderma Gangrenosum: Review and Assessment of Disease Effects) Group
47. Wound care for patients with hidradenitis suppurativa: Recommendations of an international panel of experts
48. Hidradenitis suppurativa in transgender and gender diverse patients: a retrospective review with examination of the role of hormone therapy
49. A Systematic Review of Promising Therapeutic Targets in Hidradenitis Suppurativa: A Critical Evaluation of Mechanistic and Clinical Relevance
50. Proceeding report of the Fourth Symposium on Hidradenitis Suppurativa Advances 2019
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.